Overall, these studies support CA3 as a therapeutic approach in selected CCA models and suggest that combinatorial approaches with AR‐directed inhibitors should be considered in the setting of YAP‐TEAD targeting. The gene discussed is AR; the disease is cholangiocarcinoma.